Ivosidenib as Post-HSCT Maintenance for AML
Ivosidenib as Post-HSCT Maintenance for AML
Recruiting · NCT06707493 · Registry updated 2026-10-05Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Ivosidenib as Post-HSCT Maintenance for AML | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, acute myeloid leukemia, hematologic disorder, leukemia, myeloid leukemia, neoplasm | Recruiting | Phase 2 | 2026-10-05 | NCT06707493 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Massachusetts General Hospital | 758 |
| Servier | 21 |
7 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Dana Farber Cancer Institute | Boston | United States | 133 |
| Emory University Hospital | Atlanta | United States | 131 |
| Froedtert Hospital & the Medical College of Wisconsin | Milwaukee | United States | 31 |
| Huntsman Cancer Institute, University of Utah | Salt Lake City | United States | 45 |
| Kansas University Medical Center | Kansas City | United States | 25 |
| Massachusetts General Hospital | Boston | United States | 1015 |
| Ohio State University Wexner Medical Center- James Cancer Hospital | Columbus | United States | 2 |